Given the key epigenetic involvement of HDAC6 in the autophagic process and the controversial role of autophagic machinery in promoting or blocking tumor development, designing a tailored therapy for different cancer types based on the use of specific HDAC6 inhibitors could be a valid approach. This evidence concerns the gene HDAC6 and cancer.